Work

Treatment of Frey's Syndrome With “Ready to Use Liquid” Relabotulinumtoxin A (Relfydess)

Year: 2026

Type: article

Abstract: ABSTRACT Objective To describe the off‐label intradermal use of ready‐to‐use liquid relabotulinumtoxinA (Relfydess) for symptomatic Frey's syndrome after parotidectomy. Methods A 72‐year‐old man with gustatory sweating and flushing after total parotidectomy and adjuvant radiotherapy, who had previously responded to conventional botulinum toxin A, underwent gustatory provocation, clinical mapping, and intradermal relabotulinumtoxinA injections using a 1‐cm 2 grid. Clinical response and treatment‐related adverse events were assessed at 6 weeks and 3 months. Results At 6 weeks and 3 months, the patient reported symptom reduction comparable to his previous treatment with conventional botulinum toxin A. At 3 months, repeat gustatory stimulation elicited no visible sweating. No treatment‐related adverse events were observed. Conclusion In this patient, ready‐to‐use liquid relabotulinumtoxinA provided sustained symptom control for 3 months without observed adverse events. This formulation may offer a practical off‐label option for previously responsive patients, while product‐specific potency units should not be considered interchangeable. Level of Evidence 5

Source: Laryngoscope Investigative Otolaryngology

DOI: 10.1002/lio2.70618

Authors: Loris Zoller, Philipp Reddiess, Justus Müller‐Goebel, Tobias Kleinjung, Daniel Runggaldier

Institutions: University of Zurich, University Hospital Zurich

Language: English

Topic: Sympathectomy and Hyperhidrosis Treatments

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,900